Published in Wien Klin Wochenschr on September 29, 2011
Benefits and pitfalls of cardiovascular medication in seniors. Wien Klin Wochenschr (2013) 0.80
Are there differences in LDL-C target value attainment in Austrian federal states? Yes! Wien Med Wochenschr (2013) 0.75
Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid. ScientificWorldJournal (2013) 0.75
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet (2009) 5.84
Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol (2004) 4.07
Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol (1988) 2.22
New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep (2007) 1.26
Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation (2001) 1.19
High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J (2002) 1.01
Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis (2009) 0.82
[Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP)]. Wien Klin Wochenschr (2008) 0.78
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care (2009) 2.50
Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction. Eur Heart J (2010) 2.01
Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J (2006) 2.00
Women and heart disease: the role of diabetes and hyperglycemia. Arch Intern Med (2004) 1.63
Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol (2002) 1.62
The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J (2004) 1.46
Gender differences in acute non-ST-segment elevation myocardial infarction. Am J Cardiol (2006) 1.16
Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus. Am J Cardiol (2009) 1.07
Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry. BMC Endocr Disord (2012) 1.05
Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol (2012) 1.03
Incidence and clinical impact of stroke complicating percutaneous coronary intervention: results of the Euro heart survey percutaneous coronary interventions registry. Circ Cardiovasc Interv (2013) 0.99
Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. Cardiovasc Diabetol (2010) 0.97
Chronic total coronary occlusions in patients with stable angina pectoris: impact on therapy and outcome in present day clinical practice. Clin Res Cardiol (2009) 0.96
Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina. Int J Cardiol (2010) 0.95
Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil (2010) 0.94
Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry. Cardiovasc Diabetol (2011) 0.91
Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J (2006) 0.91
Prima-vista multi-vessel percutaneous coronary intervention in haemodynamically stable patients with acute coronary syndromes: analysis of over 4.400 patients in the EHS-PCI registry. Int J Cardiol (2011) 0.87
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol (2013) 0.87
Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. Curr Med Res Opin (2012) 0.84
Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill? Diabetes Care (2008) 0.84
Clinical practice of primary angioplasty for the treatment of acute myocardial infarction in Germany: results from the MITRA and MIR registries. Z Kardiol (2002) 0.84
Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy--an analysis of the DiaRegis registry. Cardiovasc Diabetol (2013) 0.83
Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J (2006) 0.83
RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. BMC Cardiovasc Disord (2012) 0.83
Use and outcomes of multivessel percutaneous coronary intervention in patients with acute myocardial infarction complicated by cardiogenic shock (from the EHS-PCI Registry). Am J Cardiol (2012) 0.82
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice. J Thromb Thrombolysis (2008) 0.81
Multivessel percutaneous coronary intervention in patients with stable angina: a common approach? Lessons learned from the EHS PCI registry. Heart Vessels (2011) 0.81
Gender differences in therapeutic recommendation after diagnostic coronary angiography: insights from the Coronary Angiography and PCI Registry of the German Society of Cardiology. Clin Res Cardiol (2015) 0.80
Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: insights from the Euro heart survey PCI registry. Catheter Cardiovasc Interv (2011) 0.79
The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost (2017) 0.78
Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. BMC Cardiovasc Disord (2014) 0.77
Highlights of the 2007 scientific sessions of the European Society of Cardiology Vienna, Austria, September 1-5, 2007. J Am Coll Cardiol (2007) 0.77
Body mass index and effectiveness of reperfusion strategies: implications for the management of patients with ST-elevation myocardial infarction. J Interv Cardiol (2008) 0.76
Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics. Clin Res Cardiol (2010) 0.75
Are there differences in LDL-C target value attainment in Austrian federal states? Yes! Wien Med Wochenschr (2013) 0.75
Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. Vasc Health Risk Manag (2013) 0.75
Highlights of the 2006 scientific sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006. J Am Coll Cardiol (2006) 0.75
Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. Acute Card Care (2008) 0.75
Left circumflex artery-related myocardial infarction: does ST elevation matter? Results from the Euro Heart Survey PCI registry. Int J Cardiol (2013) 0.75
[Actual clinical practice of guideline-recommended therapy of acute ST elevation myocardial infarction]. Herz (2005) 0.75